Synexa Life Sciences (Pty) Ltd. based in Cape Town, South Africa, has agreed to collaborate with ImmunoTech Laboratories Inc in their research activities to demonstrate the immunological activities of their propriety Irreversible Pepsin Fraction (IPF) which has shown to have potent adjuvant properties.
This new venture follows from a preliminary clinical study conducted in South Africa in HIV-infected patients where clear immune markers demonstrated long term benefit in the treated subjects enrolled in the study. At the time, no defined immune mechanisms of action of IPF were known.
However, the new scientific venture between Synexa and Immunotech proposes to investigate the underlying mechanisms of immune regulation and the potential role of IPF in modulating such responses. The ultimate aim is to develop a portfolio of scientific data to be investigated clinically.
Synexa is a leading biomarker laboratory with its main laboratories in Cape Town but with an operation based in London, United Kingdom. It provides a full service offering from method development to interpretation of results during a clinical study.
As Chief Scientific Officer, I am excited at the prospects of working in close collaboration with Immunotech, especially having seen results from the HIV study conducted in South Africa.
I remain at your disposal should any further details be required.
Prof Patrick JD Bouic